| Name | Title | Contact Details |
|---|---|---|
Dan Jamieson |
Associate Director Enterprise Architecture | Profile |
Diana Atwell |
Associate Director, Information Systems | Profile |
The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Ayudamos a los agricultores a maximizar sus cosechas con el mínimo de recursos y sin riesgos para la salud humana, animal y del medioambiente
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.